# Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

> **NCT03826628** · PHASE2,PHASE3 · COMPLETED · sponsor: **Dermatology Specialties Limited Partnership** · enrollment: 107 (actual)

## Conditions studied

- Facial Angiofibroma
- Tuberous Sclerosis

## Interventions

- **DRUG:** rapamycin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03826628
- **Lead sponsor:** Dermatology Specialties Limited Partnership
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-28
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2023-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03826628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03826628, "Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03826628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*